Alemtuzumab therapy for leukemic cutaneous T-cell lymphoma: diffuse erythema as a positive predictor of complete remission.
Harvard Skin Disease Research Center, Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts.
Rei
R
Watanabe
Harvard Skin Disease Research Center, Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts.
Jessica E
JE
Teague
Cutaneous Lymphoma Program, Dana-Farber Brigham and Women's Cancer Center, Boston, Massachusetts.
David C
DC
Fisher
Harvard Skin Disease Research Center, Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts2Cutaneous Lymphoma Program, Dana-Farber Brigham and Women's Cancer Center, Boston, Massachusetts.
Thomas S
TS
Kupper
Harvard Skin Disease Research Center, Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts.
Rachael A
RA
Clark
D000074323:Alemtuzumab; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004890:Erythema / Q000139:chemically induced / Q000473:pathology*; D006801:Humans; D060828:Induction Chemotherapy / Q000379:methods; D007938:Leukemia / Q000150:complications / Q000188:drug therapy*; D016410:Lymphoma, T-Cell, Cutaneous / Q000150:complications / Q000188:drug therapy*; D012878:Skin Neoplasms / Q000150:complications / Q000188:drug therapy*; D016896:Treatment Outcome
D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000074323:Alemtuzumab